See Local News
Get Balanced News From Your U.S. State.
See Local News
See all locals

What’s next in Medicare price negotiation

Posted on AllSides August 29th, 2023
From The Center

The medications announced on Tuesday target highly common diseases in the U.S., such as heart disease, heart failure, rheumatoid arthritis and diabetes. The selection included insulin drug NovoLog, blood thinner Eliquis, antidiabetic Jardiance and leukemia drug Imbruvica, as well as a more unanticipated pick: Stelara, which is used to treat Crohn’s disease. The drugs chosen for initial Medicare price negotiation were picked based on a very specific set of guidelines. They couldn’t be “orphan drugs” (medications for diseases so rare that manufacturers have little incentive to develop them without government...

Read full story

AllSides Picks

More News about Healthcare from the Left, Center and Right

From the Left

From the Center

From the Right